ADIPOQ and Alzheimer disease: Although adiponectin exerts neuroprotective and insulin-sensitizing actions, clinical studies have reported heterogeneous circulating levels in dementia, including elevations in established AD, a phenomenon sometimes interpreted as a compensatory response or ‘adiponectin resistance [185,186].